University of Alabama at Birmingham
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Alabama at Birmingham sits in the top decile of US sponsors by registered trial count (#26 of 15,742 sponsors by registered trial count).
University of Alabama at Birmingham: 1,160 sponsored US clinical trials, 216 recruiting.
University of Alabama at Birmingham sponsors 1,160 registered US clinical trials on ClinicalTrials.gov, 216 of them currently recruiting, and 723 completed. 97 of these trials are in Phase 3-4 (later-stage) and 259 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 15 trials.
Top-decile sponsor footprint
University of Alabama at Birmingham ranks in the top decile of sponsors by registered trial count (#26 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
723 of 812 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,160 total, page 23 of 24
A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer
NCT00584857
Pancreatic and Gastrointestinal Tumor Registry and Tissue Collection
NCT00584363
Risperidone and Suicidality in Major Depressive Disorder
NCT00167154
HIV Prevention in the Primary Care Setting
NCT00381524
Pilot Study of Pentoxifylline for Hepatopulmonary Syndrome
NCT00593658
Comparison of School-Based Supervised Versus Parental Supervised Asthma Therapy
NCT00110383
Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)
NCT00259610
Admixture Mapping of Ethnic and Racial Insulin Complex Outcomes
NCT00726778
Longitudinal Efficacy of Dental Implants in Anterior Areas
NCT00641277
Frequency of Aerobic/Resistance Training in Older Women
NCT01031394
Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia
NCT00081822
Dental Tobacco Control.Net:Improving Practice
NCT00627185
A Phase I Study of ABT 510 for Newly Diagnosed Glioblastoma Multiforme
NCT00584883
Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder
NCT00204347
High Dose CVVHDF Compared to Standard Dose CVVHDF
NCT00561431
Intramedullary Nailing of the Femur:Trochanteric vs Piriformis Starting Portals
NCT00593333
Trial of Foley Catheter With and Without Extra-Amniotic Saline Infusion for Labor Induction
NCT00442663
Control of Trichomoniasis
NCT00334555
Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer
NCT00062270
Paclitaxel and Carboplatin in Treating Women Who Are Undergoing Surgery for Newly Diagnosed, Locally Advanced Breast Cancer
NCT00096343
Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck
NCT00318890
Radiosensitization With Celecoxib and Chemoradiation for Head and Neck Cancer
NCT00581971
To Examine Smoking Behavior of Prisoners - 1
NCT00115674
Treatment of Bacterial Vaginosis
NCT00324818
Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases
NCT00582075
CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer
NCT00033384
BMS-247550 in Treating Patients With Metastatic Colorectal Cancer
NCT00033306
Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer
NCT00318903
Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib
NCT00582660
Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy
NCT00086736
Vacuum Assisted Closure as a Treatment for Draining Hematomas
NCT00582179
Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00033423
Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer
NCT01004731
Vacuum Assisted Closure as a Treatment for Open Fractures
NCT00582361
Vacuum Assisted Closure as a Treatment for Soft Tissue Injuries
NCT00582998
AG2037 in Treating Patients With Advanced, Metastatic, or Recurrent Solid Tumors
NCT00017524
Antiproteinuric Agents and Fabry Disease
NCT00343577
Exercise Training in Obesity-prone Black and White Women
NCT00067873
Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura
NCT00005652
Analyzing How Genetics May Affect Response to High Blood Pressure Medications
NCT00563901
Compass Hinge Stabilization of Knee Dislocations: A Randomized Trial
NCT00582517
Improving Vision and Quality of Life in the Nursing Home
NCT00347620
ISIS 2503 in Treating Patients With Advanced Cancer of the Pancreas
NCT00005594
Open Reduction Internal Fixation of Calcaneus Fractures With and Without Bone Graft
NCT00582686
Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Surgically Removed
NCT00004160
Gemcitabine Plus Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Solid Tumor
NCT00004159
Comparison Between LISS Plating and Intramedullary (IM) Nailing for Supracondylar Femur Fractures
NCT00578019
Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00005592
Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis
NCT00004196
Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx
NCT00004227
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 129 |
| Phase 2 | 130 |
| Phase 3 | 25 |
| Phase 4 | 72 |
Therapeutic Areas
What is open in the University of Alabama at Birmingham pipeline
216 recruiting of 1,160 indexed (19% open); 723 completed (62%).
Phase mix: 97 late (III/IV) vs 259 early (I/II) (early-phase heavy).
Top condition: Obesity (15 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Alabama at Birmingham: open-pipeline peers nationwide
Peers matched on 1,160 registered trials and 19% open enrollment, not the therapeutic-area sidebar.
University of Alabama at Birmingham sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,160 trials (± recruiting share)
- NYU Langone Health · 1,164 trials · 17% recruiting
- Wake Forest University Health Sciences · 1,140 trials · 15% recruiting
- Emory University · 1,208 trials · 17% recruiting
- Northwestern University · 1,209 trials · 15% recruiting
Sponsors near 19% open enrollment (± trial volume)
- University of Minnesota · 19% recruiting · 966 trials
- Mclean Hospital · 19% recruiting · 140 trials
- Children's Hospital Medical Center, Cincinnati · 19% recruiting · 571 trials
- Arkansas Children's Hospital Research Institute · 19% recruiting · 97 trials
Related
What to do with this University of Alabama at Birmingham page
1,160 registered trials is a research-attention snapshot, not an endorsement of University of Alabama at Birmingham or any single study.
- 216 of University of Alabama at Birmingham's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition University of Alabama at Birmingham studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Alabama at Birmingham pipeline card: 1,160 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.